Assessment of C-Reactive Protein/Albumin Ratio and Other Inflammatory Markers in Rosacea: A Case–Control Study

Background: Although rosacea is a persistent inflammatory illness, a specific parameter capable of demonstrating its severity has not been established. This study examined C-reactive protein (CRP) and CRP/ albumin ratio (CAR) levels in rosacea patients, comparing them with those in healthy control groups and investigating their relationship with disease severity. Methods: This study is a prospective cross-sectional study. C-reactive protein, albumin, CAR, platelet, neutrophil, lymphocyte, and monocyte levels were measured in patients diagnosed with rosacea who presented to the Dermatology Clinic over a 1-year period. The results were statistically evaluated by comparing them with the values of a healthy control group. Results: The mean CRP level in patients with rosacea was 3.0 ± 3.3 mg/dL and the CAR level was 0.9 ± 0.9. In the control group, these values were 1.8 ± 1.7 mg/dL and 0.58 ± 0.51, respectively. Compared with healthy controls, the rosacea group showed markedly higher CRP and CAR concentrations, supported by significant P-values (.014 and .028). In the receiver operating characteristic analysis, the area under the curve was found to be 0.59 for CRP and 0.58 for CAR. A CRP value above 1.88 mg/dL showed 48.3% sensitivity and 70% specificity, while a CAR value above 0.98 showed 31.6% sensitivity and 88.3% specificity. Conclusion: Elevated CRP and CAR levels support the presence of systemic inflammatory activity in rosacea. Although both CRP and CAR levels are elevated in patients with rosacea, in this study, neither marker showed a significant association with disease severity. According to the study, CRP and CAR may be more meaningful and useful than other classic inflammatory parameters for determining the inflammatory burden in patients with rosacea. Cite this article as: Soğuksu AO, Pala E. Assessment of C-reactive protein/albumin ratio and other inflammatory markers in rosacea: a case–control study. Eurasian J Med. 2026, 58(4), 1468, doi: 10.5152/eurasianjmed.2026.261468.